Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Patent Litigation
  5. Patent

Patent

Thumbnail
May 30, 2022

Abbvie to become the biggest of pharmas in 2028

New extended consensus forecasts from Evaluate Pharma show Roche edged out of first place by Abbvie as new blood replaces Humira.

Thumbnail
May 25, 2022

The patent winter is coming

Biopharma is approaching the most painful period of patent loss for at least 30 years. Is M&A an answer?

Article image
Vantage logo
May 23, 2022

Concert alopecia win rubs Salt in its wounds

Article image
Vantage logo
March 11, 2022

Alvotech settlement completes the list of Humira challengers

Article image
Vantage logo
May 06, 2021

Biden patent waiver unlikely to hit vaccine sales

Article image
Vantage logo
September 03, 2020

Amarin forced to look to Europe as US patent hopes dashed

Article image
Vantage logo
August 20, 2020

Mylan only the first chink in Tecfidera’s armour

Article image
Vantage logo
August 06, 2020

Eliquis patent win adds a few billion to Bristol and Pfizer

Article image
Vantage logo
July 27, 2020

Curevac muddies the Moderna/Arbutus waters further

The markets try to figure out who really benefits from last week’s patent decision over a key mRNA technology.

Article image
Vantage logo
July 24, 2020

The Covid-19 vaccine battle just got interesting

A patent claim against Arbutus is thrown out, threatening parts of Moderna’s mRNA technology – including its Covid-19 vaccine.

Article image
Vantage logo
July 10, 2020

Glaxo's HIV prevention win should lead to upgrades

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

June 16, 2022

Vantage Top 10 Most Read Report

June 15, 2022

Asco 2022 eBook

View more...

Editor's Picks

Vantage logo
June 14, 2022

Roche deal fails to Repare the licensing scene

Vantage logo
June 13, 2022

EHA 2022 – Crispr still looks bloody good

Vantage logo
June 05, 2022

Asco 2022 – Enhertu asks, how low can you go?

Vantage logo
June 09, 2022

Asco 2022 movers – cell therapy wins, but it’s not the whole story

Vantage logo
May 30, 2022

Abbvie to become the biggest of pharmas in 2028

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.